406 related articles for article (PubMed ID: 21496485)
1. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
2. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
Wang K; Zhang X; Zhang L; Qian L; Liu C; Zheng J; Jiang Y
Drug Deliv; 2015 May; 22(3):389-99. PubMed ID: 24670095
[TBL] [Abstract][Full Text] [Related]
3. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.
Zhu S; Hong M; Tang G; Qian L; Lin J; Jiang Y; Pei Y
Biomaterials; 2010 Feb; 31(6):1360-71. PubMed ID: 19883938
[TBL] [Abstract][Full Text] [Related]
4. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
5. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation.
Zhu S; Hong M; Zhang L; Tang G; Jiang Y; Pei Y
Pharm Res; 2010 Jan; 27(1):161-74. PubMed ID: 19862607
[TBL] [Abstract][Full Text] [Related]
6. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
7. Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy.
Zhang X; Yao S; Liu C; Jiang Y
Biomaterials; 2015 Jan; 39():269-81. PubMed ID: 25468377
[TBL] [Abstract][Full Text] [Related]
8. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
[TBL] [Abstract][Full Text] [Related]
9. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
10. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
[TBL] [Abstract][Full Text] [Related]
11. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
12. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.
He H; Li Y; Jia XR; Du J; Ying X; Lu WL; Lou JN; Wei Y
Biomaterials; 2011 Jan; 32(2):478-87. PubMed ID: 20934215
[TBL] [Abstract][Full Text] [Related]
13. cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo.
Zhong Y; Wang C; Cheng R; Cheng L; Meng F; Liu Z; Zhong Z
J Control Release; 2014 Dec; 195():63-71. PubMed ID: 25108151
[TBL] [Abstract][Full Text] [Related]
14. Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations.
Liu G; Shen H; Mao J; Zhang L; Jiang Z; Sun T; Lan Q; Zhang Z
ACS Appl Mater Interfaces; 2013 Aug; 5(15):6909-14. PubMed ID: 23883622
[TBL] [Abstract][Full Text] [Related]
15. PEGylated Polyamidoamine dendrimer conjugated with tumor homing peptide as a potential targeted delivery system for glioma.
Jiang Y; Lv L; Shi H; Hua Y; Lv W; Wang X; Xin H; Xu Q
Colloids Surf B Biointerfaces; 2016 Nov; 147():242-249. PubMed ID: 27518456
[TBL] [Abstract][Full Text] [Related]
16. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
17. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of stimuli-responsive vesicle from PEGylated hyperbranched PAMAM-doxorubicin conjugate for gastric cancer therapy.
Nie J; Wang Y; Wang W
Int J Pharm; 2016 Jul; 509(1-2):168-177. PubMed ID: 27234696
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fu F; Wu Y; Zhu J; Wen S; Shen M; Shi X
ACS Appl Mater Interfaces; 2014 Sep; 6(18):16416-25. PubMed ID: 25185074
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
